The restriction site mutation (RSM) assay was used to study the mutational sensitivities of three target regions of the murine p53 gene. The non-coding intron 6 target region was compared with the coding regions exon 4 and exon 5 with respect to their relative sensitivity to the induction of mutations by 1,2-dimethylhydrazine (DMH). Our results demonstrated that the majority of induced mutations detected were in the intron 6 gene region. A total of 15 enzyme-resistant restriction sites were detected in DMH treated mice, nine of these in the intron 6 region, four in the exon 4 region and two in the exon 5 region. The elevated sensitivity of the intron 6 region was exemplified by our detection of spontaneous mutations in this region; two resistant restriction sites were detected in untreated animals. No spontaneous mutations were detected in either of the exon sequences studied here, nor have any been detected in exon targets in our previous in vivo RSM analyses. The mutations induced by DMH were mostly GC->AT transitions, as were the spontaneous mutations identified. The mutation frequencies calculated by the inclusion of a mutant internal standard (MIS) in the RSM method, revealed that the non-coding intron 6 region and the exon 4 region had a 10-fold higher mutation frequency than the exon 5 region. This heterogenous distribution of mutations and their differential mutation frequencies, were probably a consequence of the greater selection in the coding regions inp53 function. However, the actual mechanism of differential mutation induction is, as yet, to be defined.
Introduction
The aim of this investigation was to examine in vivo mutations induced in intron 6 of the murine p53 gene. Intron 6 was compared with exon 4 and exon 5 with respect to its sensitivity to mutation induction by 1,2-dimethylhydrazine (DMH) and also to the presence of spontaneously arising mutations.
Current mutational tests generally involve phenotypic detection. However, these systems are limited in their ability to detect the potential genotoxicity of chemicals due to their reliance on a small subset of genes which give rise to selectable phenotypes (usually drug resistance) and the need for an expansion step in vitro (for a review see Albertini et al, 1990) .
With the advent of polymerase chain reaction (PCR) technology (Saiki et al, 1988) , it is theoretically possible to detect rare mutant DNA sequences amongst a pool of wild-type DNA sequences. The development of such genotype-based mutation detection systems should allow the selection of mutants at the level of the DNA. The genotypic systems can also offer additional information about the base specificity of genotoxins and the relevance of sequence context in mutagenesis. The use of genotypic mutation detection systems which employ endogenous target genes may reflect the in vivo effect of genotoxins and do not require extrapolation from mutational data obtained using exogenous targets, such as transgenes.
The restriction site mutation (RSM) assay is a genotypic mutation detection system which utilizes normal host target genes (Zijlstra et al, 1990; Parry et al, 1990; Felley Bosco etal, 1991; Sandy et al, 1991; Chioccaef al, 1992; Pourzand and Cerutti, 1993) and detects mutations induced in restriction enzyme sites in target DNA regions. The assay is applicable to any sequenced gene of any organism. A series of RSM studies in bacteria and cultured mammalian cells has recently been reveiwed by Steingrimsdottir et al. (1996) . The key steps in the RSM assay are outlined in Figure 1 . In this study we have investigated the use of an internal standard molecule in the RSM assay. The inclusion of a known copy number of the mutant internal standard (MIS) in the PCR step allows the quantification of the mutation frequency of the resistant RSM products. This quantification is possible, due to the amplification efficiency of the MIS and the target sequence being identical (Siebert and Larrick, 1993) . In addition, because the ratio of MIS to target sequence remains constant throughout the amplification, it is not essential to sample before the exponential phase of the PCR reaction ends (Siebert and Larrick, 1992) . In previous reports, the sensitivity of the RSM assay has been shown to be ~ 10~5 (Suzen, 1996) . This represents the minimum detection limit of 10 mutant molecules in 1 ug of DNA and is consistent with the published sensitivity of the RSM assay (Steingrimsdottir et al, 1996) . This sensitivity can be improved by repeated analysis and average mutation frequencies as low as 10" 6 -10~7 can be estimated from such data. In this study the RSM assay was evaluated using the murine p53 as the genomic target.
The p53 tumour suppressor gene was chosen for this investigation because mutations in this gene are the most frequent genetic alteration associated with many types of human tumours (Nigro et al, 1989; Hollstein et al, 1991) . The association of p53 mutations with tumour formation is a consequence of its central role in protecting the genome from DNA damage via cell cycle control and regulation of apoptosis (Yonisch Rouach et al, 1991; Lane, 1992) . The structure of the murine p53 gene is shown in Figure 2 . The mutations identified in tumours are clustered in four evolutionarily conserved domains of the p53 gene (Soussi et al, 1990) . The vast majority of these mutations fall in the second domain, corresponding to exons 5-8 of the p53 gene ( Hollstein et al, 1991) . This domain encodes the DNA binding region of the p53 molecule (Cho et al, 1994) .
In our study p53 mutations were induced by the alkylating agent DMH. Alkylating agents represent one of the largest classes of chemical mutagens and have been extensively (Thurnherr et al, 1973) by the cytochrome P-450 monooxygenases (Turosov et al, 1988) . These metabolites create a reactive methylcarbonium ion with methylating potential (Sangwick et al, 1992) . We used the RSM assay to analyse mutations induced in three regions of the murine p53 gene. The induced mutations were determined in exon 4, exon 5 and intron 6. Exon 5 lies in the second evolutionary conserved region (Soussi et al, 1990) which is involved in DNA binding (Cho et al, 1994) . Mutations in exon 5 are detected in many tumours indicating their importance in the aetiology of cancer. Exon 4 mutations are rare in tumours (Nigro et al, 1989) and hence mutations in this region are probably less or non-essential to p53 function. The non-coding intron 6 gene region is probably the least important of the regions studied with respect to p53 function. The vast majority of mutations induced in this intron region being silent. These three genomic regions of the p53 gene differ in their importance to p53 function and as such, could be predicted to display different mutational characteristics with regard to both frequency and types of mutations.
In this paper we report the detection of mutations in DMH treated mouse liver using the RSM assay. DMH treatment resulted in an ~ 100-fold increase in mutation frequency over untreated animals. Mutations were shown to be induced in all three regions of the p53 gene. However, the distribution of these mutations identified the intron 6 gene region as being particularly sensitive to mutation induction. This sensitivity was also demonstrated by the detection of background (spontaneous) mutations in untreated animals which were not present in either exon region. Spontaneous mutations were not reported in previous in vivo studies using the RSM assay (Kennerley and Parry, 1993; Myers and Parry, 1994) .
Materials and methods

Dosing of animals
Male CD-I outbred albino mice (Charles River UK Ltd, Manston, UK) were dosed orally by gavage with water (negative control) or with 20 mg/kg/day DMH (Sigma-Aldrich Co. Ltd, Poole, UK) dissolved in water. The mice were dosed on 2 consecutive days at a dose volume of 10 ml/kg and the animals were killed on day three, 24 h after the second dose was administered. The cadavers were stored at -70°C until dissection and DNA extraction. DNA was extracted by a modified high salt precipitation method of Miller et al. (1988) . The concentration and purity were determined by spectrophotometry. The concentration of DNA was adjusted to 0.1 (ig/|xl and stored at -20°C.
RSM assay analysis
RSM analysis was performed on 1 |ig aliquots of control and DMH treated DNA derived from liver tissue. The initial digestion was carried out overnight with 8-12 U of appropriate enzyme in Taq polymerase thermo buffer (Promega, Madison, WI, USA) supplemented with 1.5 mM MgCl 2 , in a final volume of 20 u.1. An extra 8-12 U of the enzymes were added the next morning and incubation at 37°C continued for 1 h. The target restriction sites analysed in this study were as follows: exon 4: Banll, Ncol, Alul; exon 5: HaelU, Ncol, MalV; intron 6: Banll, Haelll. The restriction enzyme sites analysed by RSM and their relative locations within the murine p53 gene are depicted in Figure 2 .
The amplification of undigested molecules was performed with 2.5 U of Taq DNA polymerase (Promega) in Thermo buffer (10 mM Tris-HCl, pH 8.8, 50 mM KC1, 0.1% Triton X-100) along with 1.5 mM MgCl 2 , 100 nM each dNTP, 10 pmoles of each PCR primer and -100 copies of the mutant internal standard (see below) the reaction volume was adjusted to 50 JJ. 1 with distilled deionized water. The PCR primer sequences used in this study are given in Table I and their position within the p53 gene are shown in Figure  2 . Note that the forward primer for each target region (4.1, 5.1, 6.1) was fluorescein-labelled and the reverse primer (4.2, 5.2, 6.2) was labelled with biotin. Amplification was carried out using a 'DNA engine' (MJ Research, Watertown, MA, USA). The amplification reaction was initially incubated at 94°C for 2 min in order to completely denature the templates. The temperatures, times and cycle numbers were optimized the amplification of each gene region. The conditions employed for the amplification of DNA in the exon 4 and the intron 6 gene regions were as follows: (i) denaturing at 94°C for 30 s; (ii) annealing at 60°C for 15 s; and (iii) extension at 72°C for 20 s, 33 thermal cycles were performed. The thermal profile for the exon 5 gene region was essentially the same except that annealing was achieved at 55°C and 31 cycles were performed. The amplified product was then subject to a second restriction digest. Aliquots of PCR amplified DNA (16 ng) were digested with 8-12 U of enzyme in the manufacturer's recommended buffer. The digestion mixture was incubated overnight at 37°C.
Synthesis of the MIS and its application in quantitative PCR
In order to determine the frequency of mutations detected in the RSM assay, an MIS was included in the PCR step.
The detailed synthesis of the MIS molecules for each gene region analysed will be described elsewhere, briefly, they were constructed by the annealing and extension of megaprimers synthesized on a 391 PCR MATE DNA synthesizer (ABI, Warrington, UK). The MIS constructs were synthesized with deleted or mutated target restriction sites employed in RSM and were 20-30 bases shorter than the full size PCR product to allow identification. The MIS molecules were amplified by PCR and cloned into pCR e II vector (Invitrogen, NV LEEK, The Netherlands) by use of the 3' adenosine overhangs created by Taq polymerase.
Visualization and quantification of resistant RSM products
Half of the final RSM product (10 ul) was loaded onto 6% polyacrylamide gels and subjected to electrophoresis in 90 mM Tris-borate, pH 8.3, 4 mM EDTA at 150 mA for 45 min at 17°C. The presence of resistant RSM products was confirmed by silver staining. Figure 3 shows a typical RSM gel. In this example the target region used was the exon 4 p53 region, giving a PCR product of 226 bp. The gel demonstrates RSM analysis of five control samples (lanes 1-5) and four genotoxin treated samples (lanes 6-9). Positive and negative PCR controls and a DNA marker are also shown (lanes 10-12). It can be seen that two of the treated samples (lanes 6 and 8) contain resistant RSM products, whilst the other two treated samples and the control samples digest completely. The MIS molecule is also visible at 186 bp in all lanes and in the negative control. Resistant products, such as those in Figure 3 , can be quantified by use of an automated laser fluorescence (ALF) DNA sequencer (Pharmacia, Uppsala, Sweden). An aliquot of 1-2 ul of the remaining RSM product can be loaded onto the ALF DNA sequencer and the amount of fluorescence contained in the RSM product was compared with that in the MIS band using the Fragment Manager Software (Pharmacia). The mutation frequency of the resistant RSM product was calculated from the equation (adapted from Porcher et al, 1992) : Number of mutant molecules = (QRSM/QMIS)XCMIS Where QRSM = amount of fluorescence in RSM band; QMIS = amount of fluorescence in MIS band; CMIS = copy number of MIS included in PCR step; mutation frequency = number of mutant molecules/3 X10 5 ; 3X10 5 = copy number of p53 gene in 1 |lg of genomic DNA. This calculated mutation frequency was adjusted to take into account the proportion of RSM analyses which resulted in a resistant RSM product, that is, an average mutation frequency was obtained. For example, if two resistant RSM products were obtained in the exon 4 target region, both with a mutation frequency of 1X 10~5, but in 18 other duplicate assays no resistant bands were detected, then the mutation frequency would be reduced by a factor of 1/10 to create an average mutation frequency for the target region: this would give a final figure of 1X10" 6 in this example.
Sequencing of the resistant RSM product
The remaining 8 (il of RSM product was electrophoresed on 6% polyacrylamide gels, in the same manner as mentioned above. However, these gels were stained with ethidium bromide and the resistant RSM product band was excised from the gel under UV transillumination. The resistant bands were purified by the use of spin X columns (Costar, Cambridge, MA, USA). The liquid collected was amplified by PCR using the same primers and conditions as described earlier except a lower cycle number of 20-25 cycles was employed. The PCR amplified resistant band was directly sequenced using an Autoload sequencing kit (Pharmacia) The sequencing reaction was performed using fluorescent sequencing primers nested 20-30 bases within the PCR product.
The sequencing reactions were loaded onto an ALF DNA sequencer (Pharmacia) and run following the manufacturer's recommended conditions. Resistant bands which contained only wild-type sequences were discarded. Multiple mutational events which occurred within one restriction site were separated into individual mutational events. However, the mutation frequencies were not assigned to the individual mutations, rather, a common mutation frequency of the restriction site was noted.
Results
RSM analysis was performed on groups of four mice treated
in vivo with DMH and also on groups of four control mice receiving the vehicle (water) only. A total of 144 RSM assays were performed: 24 on treated samples and 24 on control samples in each of the three gene regions. In the case of exon 4 and exon 5, each enzyme was employed twice, but in intron 6 where only two enzyme sites were available these enzymes were employed three times. The results revealed that mutations were induced by DMH in exons 4 and 5 and intron 6 of the p53 gene in the liver of the treated mice. However, mutations were found in intron 6 only in untreated animals. The mutations detected were heterogeneously distributed within the p53 gene (Table II) . The DMH induced mutations were almost exclusively present at GC base pairs which is consistent with previous studies on DMH induced mutagenesis (Llor et al., 1991; Jacoby et al., 1991). Mutations were found to be most prevalent in the target RSM region within intron 6 of the p53 gene, whereas the coding regions analysed by RSM (exon 4 and exon 5 of the p53 gene) contained far fewer induced mutations. In total, 15 mutant restriction sites were detected in DMH treated mice (Table II) , Of the 15 mutant restriction sites detected in the liver, nine were localized in the intron 6 target region, four in the exon 4 target region and two in exon 5 target region. The differences were analysed statistically using Fisher's exact test and the results showed that the difference in the number of mutations between the intron 6 region and the exon 5 region was statistically significant (P = 0.0182). The differences in the number of mutations between the intron 6 region and the exon 4 region or between the two exon regions were not statistically significant. The most frequently mutated restriction site was the Haelll site in intron 6 which contained six individual mutations, the Banll site in intron 6 contained five mutations. Three mutations were detected in both the Haelll site in exon 5 and the Banll site in exon 4. The two remaining mutations were detected in the Ncol site in exon 4.
The sequence specificity of DMH was confirmed to be predominantly at GC base pairs. A total of 19 mutational events were detected in total (some resistant bands when sequenced revealed more than one mutation) and 18 of these were at GC base pairs (see Table III ). The most prevalent mutations detected were GC->AT transitions, which made up 10 of the 19 DMH induced mutational events. The second most frequent mutations detected were GC->TA transversions, five of which were detected out of a total of 19 mutations. Three GC-»CG transversions were detected. Finally, one AT-»GC mutation was detected, which represented the sole mutation at AT base pairs.
As well as the 18 DMH induced mutant restriction sites, two resistant bands arising from untreated control animals were detected by RSM (Table II) . Both resistant bands from control samples were detected in the intron 6 target region, no spontaneous mutations were found in the coding regions of the p53 gene. Upon sequencing these spontaneous resistant bands, the mutations were identified as both being GC->AT transitions (Table III) . Similarly, in a separate study, spontaneous intron 6 resistant bands were detected in untreated bone marrow samples. Sequencing of these revealed that they were also mostly GC-»AT transitions, although some GC->TA transversions were detected (results not shown). In addition to a non-random distribution of p53 mutations among the three regions studied, there also appeared to be sequence-specific factors affecting their location. Of the 19 DMH induced mutations detected, 10 were found to be at sites with a 5' guanosine residue. Both mutations detected in control animals were at sites with a 5' guanosine. A possible mutational hot spot was also identified in the intron 6 gene region. A total of 10 mutations were detected in the intron 6 gene region (both treated and untreated animals), seven of which were located at the same nucleotide position. The hot spot in question was the third guanosine base in the sequence GGGCCC. This sequence contains both the BanU and the HaelH restriction sites. Figure 4 shows the base position of all of the DMH induced mutations and spontaneous mutations in the restriction enzyme sites employed in the RSM assay and demonstrates this hot spot base.
The use of quantitative PCR in the RSM assay, achieved by the inclusion of a mutant internal standard, allowed the estimation of the mutation frequency of the base substitutions detected within each of the restriction enzyme sites analysed. The mutation frequencies for the three genomic target regions were quantified and compared (Table IV) . The mutation frequency was found to be highest in the DMH treated liver tissue in the intron 6 and exon 4 target regions, both having a value of IXlOr 4 . The value for the mutation frequency in exon 5 of the DMH-treated liver was at least an order of magnitude lower at 6X10" 6 . The spontaneous mutation frequencies were calculated in a similar manner. The spontaneous mutation frequency in the intron 6 target region of the liver tissue was calculated to be 5X10" 6 . The values for the background mutation frequency for exons 4 and 5 are estimated to be >1.4X10" 6 . This value was calculated thus: there are 3X10 5 copies of the p53 gene in each RSM reaction and 24 experiments were carried out on control animals in each exon region, therefore a total of 7.2X10 6 copies were screened without finding a mutant product. Bearing in mind that 10 mutant molecules are required for detection, the mutation frequency was estimated to be <10/7.2Xl0 6 , i.e. 1.4X10"" 6 .
Discussion
The RSM assay has been successfully applied in detecting mutations induced in mice by the rodent carcinogen DMH. The results confirm that DMH is a potent liver mutagen in rodents (IARC, 1974) . These DMH induced mutations were found to be concentrated preferentially at one site within the p53 gene. The intron 6 target region was shown to be particularly sensitive to mutation induction by DMH and was also shown to contain spontaneous mutations (Table II) . This is the first report of spontaneous mutations being detected by an in vivo RSM assay. The mutations detected by RSM were almost all GC base substitutions (Table IV) . The results obtained confirmed the mutational specificity of DMH as an alkylating agent which, upon activation, induces mainly GC->AT transitions (Jacoby et al, 1991; Llor et al, 1991; Okamoto et al, 1995) . In this study, the vast majority of mutations were at GC bases with GC-»AT transitions the predominant mutation (Table III) .
A sequence-specific preference for DMH mutations was identified, DMH-induced mutations were preferentially at guanosine bases with an adjacent 5' guanosine nucleotide. This is consistent with a previous transgenic animal study, which demonstrated that the DMH induced mutations in the lad gene recovered from mouse liver were preferentially located at guanosine sites flanked by a 5' purine (Zeilmaker et al, 1991) . This preferential mutation induction may be a consequence of preferential alkylation, it has been discovered that the most permissive situation for guanosine alkylation occurs when there is a 5' guanosine present (Sendowski et al, 1991) .
The mutation frequencies detected by the RSM assay revealed that they were 10-fold lower in the exon 5 gene region compared with the exon 4 and intron 6 gene regions of DMH treated liver (Table IV) . The mutation frequency detected in untreated liver samples appeared to be marginally lower than the exon 5 gene region in DMH treated liver tissues. However, no firm conclusions can be drawn from the estimation of mutation frequency due to the relatively low numbers of mutations characterized, it is possible however to assess relative ranking of the mutation frequencies of the three regions studied. The ranking of mutation frequencies is as follows: DMH treated intron 6 and exon 4 > DMH treated exon 5 > untreated intron 6 and untreated exons.
The results indicate that the intron 6 gene region is substantially more sensitive to mutation induction than the two coding regions studied. The greater incidence of intron 6 mutations was shown to be statistically significant compared with exon 5, however the lack of statistical significance between the other regions may be a result of the small sample sizes. Of the total number of DMH induced mutations, 60% were present in intron 6 with 26% in exon 4 and only 13% in exon 5. However, perhaps more indicative of the mutational sensitivity of intron 6 is the fact that spontaneous mutations were detected in untreated liver samples in this region and have never previously been detected in exon sequences by the RSM method. The spontaneous mutation frequency detected with the RSM assay here is ~1000 times higher than for mammalian genomic DNA (Wabl et al., 1985) . This finding of spontaneous mutations in intron 6 is supported by other unpublished data (our laboratory) showing similar spontaneous mutations in intron 6 from bone marrrow tissue.
There are at least two possible explanations for the difference in mutational sensitivity displayed by different regions within the p53 gene. First, the greater sensitivity of the intron 6 gene region to mutation, compared with the two coding regions could be a consequence of selection. Non-coding intron 6 mutations might be tolerated by the cell, whereas mutations induced in key coding regions of the p53 produce variants which are likely to be selected against at the level of the cell. In this context it is interesting that intron 6 has been shown to contain a novel polymorphism that is used in discriminating mouse strains by simple strand length polymorphism (SSLP) (Okamoto et al., 1995) . Also, in a study examining molecular evolution of the APRT gene in two mice species, Turker et al. (1993) found that of the 11 sequence differences in the transcribed region only one was located in an exon sequence, the remaining mutations were all located in the intron regions and the 3' non-translated regions. Thus in these mouse strains, silent mutations which do not affect protein function appear to be tolerated. These observations support the theory that intron regions are more likely to tolerate mutations than coding regions and these accumulated mutations tend to be subject to lower levels of selection. This is in accord with these results from RSM analyses of the three gene regions studied here. Exon 5 of the p53 gene is located within an evolutionarily conserved region and seems essential for p53 function, exon 4 and particularly intron 6 are functionally less or nonimportant regions of the gene. The DMH induced mutations detected by RSM were 10-fold less prevalent in exon 5 than in the two other regions, thus implying that selection was maybe important.
However, it is unlikely that selection against DMH induced DNA damage could have occurred in such a short (3 days) expression time. An alternative explanation for the distribution of the mutations may be one of heterogenous repair. It has been well documented that actively transcribed genes are more efficiently repaired than non-transcribed genes (Bohr, 1985) and also that the transcribed strand is repaired faster than the non-transcribed strand (Mellon, 1987) . It has even been suggested that repair rates can vary between adjacent bases (Tomaletti and Pfeifer, 1994) , so it is conceivable that there are repair differences between exon and intron regions within a gene, although no such mechanism has yet been described. Before investigating which mechanism is correct, it is necessary to produce more data to confirm the work presented here.
The RSM assay is continually undergoing development and enhancements which are being investigated include the characterization of other regions of the murine p53 gene, in order to ascertain if the elevated mutation frequency detected in intron 6 is repeated in any of the other introns or in the nontranscribed 3' region. The implication that intron sequences are more mutable than exon sequences is important in the study of genotoxicity where hypermutable domains, once identified, can be employed to improve the sensitivity of genotoxicity assays. An increase in sensitivity is essential if weak genotoxins are to be characterized by current tests and this sensitivity may be further increased by the use of repair deficient mice strains. Clearly, there is considerable potential for the further development of the RSM assay as a research tool and as a routine in vivo genotoxicity test.
The RSM assay has already been developed such that it is capable of detecting rare background mutations and can be applied as a genotypic genotoxicity test with relatively high sensitivity. The RSM assay may be capable of detecting mutations in systems and tissues where currently no data is available. The assay offers significant advantages over other tests currently used; these include the assay's applicability in any gene or tissue of an organism and the fact that base specificities of mutagenesis can be monitored, as well as mutation frequency.
